Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 31, 2025.

Salvia BioElectronics’ PRIMUS system, currently being assessed in a phase 3 study, delivers subcutaneous occipital and supraorbital nerve stimulation for patients with resistant migraine.

Avi Singh Gandh, MD, neurology resident at Emory University School of Medicine, reflected on how modern neurology can interpret the Salem Witch Trials.

Patients with generalized myasthenia gravis reported a positive experience with rozanolixizumab self-administration, with a preference for the manual push method.

Data showed that efgartigimod led to greater improvements in disease activity compared with placebo in idiopathic inflammatory myopathy, and improvements in seronegative myasthenia gravis.

An analysis of the first 110 patients screened for the ARISE study showed that an independent adjudication committee confirmed the diagnosis of CIDP in nearly 3-quarters of cases.

The professor of clinical neuroscience at Newcastle University discussed selecting appropriate and representative patient populations across different phases of clinical trials for Parkinson disease. [WATCH TIME: 5 minutes]

Experts shared their clinical perspectives on trending topics in the treatment and management of multiple sclerosis at the 54th Child Neurology Society (CNS) Annual Meeting, held October 8-11, 2025.

Here's some of what is coming soon to NeurologyLive® this week.

In a recent study of patients with testicular germ cell tumors, most exhibited paraneoplastic neurologic syndromes proceeding with their cancer diagnosis, often associated with specific neural autoantibodies.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 24, 2025.

At CNS 2025, the associate professor of neurology and pediatrics at the University of Virginia discussed using educational model frameworks to prepare child neurology trainees for clinical practice. [WATCH TIME: 3 minutes]

In a recent randomized clinical trial, a smartphone-based relaxation technique provided to patients presenting to the emergency department was associated with reduced migraine-related disability.

At CNS 2025, the program director of child neurology residency at Boston Children's Hospital discussed strategies to expose medical students to child neurology early in their clinical training. [WATCH TIME: 4 minutes]

Experts shared their clinical perspectives on trending topics in the treatment and management of movement disorders at the 2025 International Congress of Parkinson’s Disease and Movement Disorders (MDS).

The president and founder of the Stuttering Treatment and Research Society highlighted the significance of interdisciplinary care for both children and adults with stuttering. [WATCH TIME: 5 minutes]

In honor of International Stuttering Awareness Day, the founder of the Stuttering Treatment and Research Society discussed understanding the diagnosis of stuttering and the importance of early intervention for patients.

A recent review of studies over the past decade, presented at CNS 2025, suggests that the ketogenic diet can significantly reduce seizure frequency in children with drug-resistant epilepsy.

A new study reported that children and adolescents with Tourette syndrome on dopamine D2 receptor antagonists had higher rates of psychiatric and metabolic adverse events than those unexposed.

The associate professor of neurology at the Icahn School of Medicine at Mount Sinai talked about the major biomarkers used to track progression in Huntington disease. [WATCH TIME: 5 minutes]

Late breaking data from a phase 1 trial presented at MDS 2025 showed that cell therapy UX-DA001 demonstrated positive efficacy in a woman with moderate-to-advanced Parkinson disease.

At MDS 2025, the senior medical director of UCB's Translational Medicine Neuroscience and Gene Therapy presented data from the ATLANTIS study of glovadalen in patients with Parkinson disease. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 17, 2025.

A phase 3 trial presented at the 2025 MDS Congress suggests that staged, bilateral magnetic resonance–guided focused ultrasound may improve motor symptoms for patients with Parkinson disease who experience motor complications.

A phase 2 study presented at 2025 MDS revealed that onabotulinumtoxinA significantly improved tremor-related disability compared with placebo in patients with upper limb essential tremor.

In phase 2a trial presented at MDS 2025, findings showed that VTX3232 achieved drug levels in plasma and cerebrospinal fluid that exceed the IC90 for NLRP3 inhibition by more than 3-fold.

The assistant professor of neurology at Oregon Health & Science University discussed emerging evidence that aerobic exercise may enhance remyelination in patients with multiple sclerosis. [WATCH TIME: 5 minutes]

New real-world data presented at MDS 2025 demonstrated that foslevodopa/foscarbidopa reduced motor fluctuations and improved quality of life in patients with advanced Parkinson disease over 6 months.

At CNS 2025, the child neurologist at Rady Children's Hospital-San Diego talked about the expanding role of genetics for diagnosis and treatment in pediatric neurology. [WATCH TIME: 5 minutes]